^
    Back
    Association details:
    Biomarker:KRAS G12C
    Cancer:Solid Tumor
    Drug:Lumakras (sotorasib) (KRAS G12C inhibitor) +
    ifebemtinib (IN10018) (FAK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    AACR-II 2020
    Title:

    Abstract LB-021: Focal adhesive kinase inhibitor IN10018 sensitizes KRAS mutant cancer and overcomes drug resistance of KRAS G12C inhibition

    Published date:
    05/15/2020
    Excerpt:
    IN10018 in combination with either AMG510 or MRTX1257 showed better effects in killing KRAS G12C cancer cells than each single treatment.
    DOI:
    10.1158/1538-7445.AM2020-LB-021